Home / Business and Economy / Fredun Pharma Doubles Profits, Expands Manufacturing Amid Rising Demand
Fredun Pharma Doubles Profits, Expands Manufacturing Amid Rising Demand
11 Nov
Summary
- Fredun Pharma's net profit more than doubled in Q3 2025
- Revenue jumped 35% to ₹145 crore, EBITDA up 60% to ₹22 crore
- Expanding manufacturing facility to meet growing domestic and international demand
On November 11, 2025, Fredun Pharmaceuticals, a prominent pharmaceutical formulation manufacturer, announced impressive financial results for the September quarter. The company's net profit more than doubled to ₹10 crore, while its revenue surged 35% to ₹145 crore compared to the same period last year. Additionally, the company's EBITDA (Earnings Before Interest, Taxes, Depreciation, and Amortization) increased by a significant 60% to reach ₹22 crore.
Fredun Medhora, the Managing Director of the company, attributed this strong performance to the solid performance of the domestic formulations business, driven by new product introductions and rising institutional demand. The exports segment also maintained steady traction during the quarter. To cater to the growing demand across both domestic and international markets, Fredun has commenced the expansion of its manufacturing facility located in Palghar.
The company also made notable progress in its pet care business. The launch of Snacky Jain, India's first Jain-friendly functional pet food, received an overwhelming response, with the entire first batch sold out through pre-orders. This launch reinforces Fredun's ethical and research-led approach to pet nutrition. Furthermore, the acquisitions of Wagr.ai and One Pet Stop have expanded the company's footprint across nutrition, technology, and services, creating a connected and science-driven pet care ecosystem.
